Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome

  • Hubmayr, Rolf Dieter, (PI)
  • Limper, Andrew Harold (PI)
  • Wheeler, Arthur (PI)
  • Moss, Marc Marc (PI)
  • Matthay, Michael A. (PI)
  • Moss, Marc (PI)
  • Morris, Alan (PI)
  • Steingrub, J.A.Y. (PI)
  • Hough, Terri (PI)
  • Deboisblanc, Bennett (PI)
  • Wiedemann, Herbert (PI)
  • Hubmayr, Rolf (PI)
  • Brower, Roy G. (PI)
  • Schoenfeld, David (PI)
  • Matthay, Michael (PI)
  • Wheeler, Arthur (PI)
  • Hite, Duncan (PI)
  • MacIntyre, Neil (PI)
  • Maxwell, Terri (PI)
  • Marathe, Anita (PI)
  • Criner, Gerard (PI)
  • Tonascia, James (PI)
  • David, Au (PI)
  • Criner, Gerard (PI)
  • Sciurba, Frank (PI)
  • Motoki, Connie (PI)
  • Cooper, J. Allen D (PI)
  • Steven, Gay (PI)
  • Gaeke Torrence, Christine (PI)
  • Albert, Richard (PI)
  • Stibolt, Thomas, B. (PI)
  • Diaz, Philip (PI)
  • Casaburi, Richard (PI)
  • Fuhlbrigge, Anne Louise (PI)
  • Tonascia, James (PI)
  • Kanner, Richard (PI)
  • Hoffman, Eric (PI)
  • Martinez, A. (PI)
  • Couper, David (PI)
  • Meilan, Han (PI)
  • Couper, David (PI)
  • Bleecker, Eugene (PI)
  • Kleerup, Eric (PI)
  • Barr, Graham (PI)
  • Woodruff, Prescott (PI)
  • Limper, Andrew (PI)
  • Bartholmai, Brian (PI)
  • Martinez, Fernando (PI)
  • Sullivan, Diane (PI)
  • Thompson, Bruce (PI)
  • Jackson, Jonathan (PI)
  • Kumar, Vikram (PI)

Project: Research project


Acute lung injury (ALI) and its more severe form, adult respiratory distress (ARD), is a devastating clinical syndrome of sudden lung inflammation that results in severe edema and hypoxemia and requires care in the intensive care unit. Mortality is between 30-40% in controlled settings. To date, no single drug has proven effective for improving mortality in ALI/ARDS despite many large and small clinical trials. The objective of the Clinical Research Network (ARDSNet) is to develop and conduct clinical research trials to prevent, treat, and improve the outcome of patients with acute lung injury, acute respiratory distress syndrome, and possibly other related critical illnesses.
Effective start/end date9/30/059/29/16


  • National Institutes of Health: $77,347.00
  • National Institutes of Health: $52,080.00


Acute Lung Injury
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Adult Respiratory Distress Syndrome
Clinical Trials
Random Allocation
Critical Illness
Pharmaceutical Preparations
Intensive Care Units
Rosuvastatin Calcium